Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 10, 2010, Pages 1887-1892

  Kanaan, Nada ^a   Claes, Kathleen ^b   Devogelaer, Jean Pierre ^a   Vanderschueren, Dirk ^b   Depresseux, Genevieve ^a   Goffin, Eric ^a   Evenepoel, Pieter ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; FIBROBLAST GROWTH FACTOR 23; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHORUS; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERAL DENSITY LOSS; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; ADULT; BELGIUM; BIOLOGICAL MARKERS; BONE DENSITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; FIBROBLAST GROWTH FACTORS; HIP JOINT; HUMANS; HYPOPHOSPHATEMIA; IMMUNORADIOMETRIC ASSAY; KIDNEY TRANSPLANTATION; LINEAR MODELS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PARATHYROID HORMONE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958533251     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00950110     Document Type: Article

References (33)

1. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33: 287-293, 1999
2. Kunzendorf U, Kramer B, Arns W, Braun J, Grossmann J, Pietruck F, Schmidt-Gayk H, Schwarz A, Ziegler E, Sperschneider H, Wüthrich RP, Nonnast-Daniel B, Schindler R, Renders L: Bone disease after renal transplantation. Nephrol Dial Transplant 23: 450-458, 2008
3. Ghanekar H, Welch BJ, Moe OW, Sakhaee K: Post-renal transplantation hypophosphatemia: A review and novel insights. Curr Opin Nephrol Hypertens 15: 97-104, 2006
4. Rojas E, Carlini RG, Clesca P, ArminioA, Sunaga O, De Elguezabal K, Weisinger JR, Hruska KA, Bellorin-Font E: The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodelling. Kidney Int 63: 1015-1923, 2003
5. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett S-A, Jüppner H, Wolf M: Post-transplant hypophosphatemia: tertiary "hyperphatoninism"? Kidney Int 70: 1486-1494, 2006
6. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y: Tertiary 'hyperphosphatonism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7: 1193-1200, 2007
7. Evenepoel P, Meijers BKI, de Jonge H, Naesens M, Bammens B, Claes K, Kuypers D, Vanrenterghem Y: Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation Clin J Am Soc Nephrol 3: 1829-1836, 2008
8. Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T: Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23: 435-440, 2005
9. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo T, Fukagawa M: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
10. Bouillon R, Van Herck E, Jans I, Tan BK, Van Baelen H, De Moor P: Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 30: 1731-1736, 1984
11. Bouillon R, De Moor P, Baggiolini EG, Uskokovic MR: A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin Chem 26: 562-567, 1980
12. Bouillon R, Coopmans W, Deqroote DE, Radoux D, Eliard PH: Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 36: 271-276, 1990
13. Devogelaer JP, Le Thi C, Depresseux G, Nagant de Deuxchaines C: Reproducibility of bone mass measurements in human volunteers using three DPA and one dual-energy X-ray bone densitometers: correlation between instruments. In: Current Research in Osteoporosis and Bone Mineral Measurements, edited by Ring EFJ, London, British Institute of Radiology, 1990, p 36
14. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD: Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325: 544-550, 1991
15. Casez JP, Lippuner K, Horber FF, Montandon A, Jaeger P: Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 17: 1318-1326, 2002
16. Torres A, García S, Gómez A, González A, Barrios Y, Concepción MT, Hernandez D, Garcia JJ, Checa MD, Lorenzo V, Salido E: Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65: 705-712, 2004
17. Heaf JG. Bone disease after renal transplantation: Transplantation 75: 315-325, 2003
18. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation: J Clin Endocrinol Metab 90: 2456-2465, 2005
19. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093-1099, 2000
20. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ: Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol Dial Transplant 10: 2096-2100, 1995
21. Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E: Bone disease after renal transplantation. Clin J Am Soc Nephrol 1: 1300-1313, 2006
22. Laan R, van Riel P, van de Putte L, van Erning L, van't Hof M, Lemmens A: Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 119: 963-968, 1993
23. Dolgos S, Hartmann A, Bonsnes S, Isaksen GA, Godang K, Ueland T, Pfeffer P, Bollerslev J: Early changes in bone mass, biochemical bone markers and fibroblast growth factor 23 after renal transplantation. Scand J Lab Invest 69: 161-167, 2009
24. Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schüler C, Erben RG, Lanske B: Evidence of serum phopshate-independent functions of FGF-23 on bone. PloS Genet 8: e10000154, 2008
25. Wang H, YoshikoY, Yamamoto R, Minamizaki T, Tanne K, Aubin JE, Maeda N: Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23: 939-948, 2008
26. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB: Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94: 511-517, 2009
27. Almond MK, Kwan JTC, Evans K, Cunnigham J: Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66: 52-57, 1994
28. Torres A, Machado M, Concepcion MT, Martin N, Lorenzo V, Hernandez D, Rodríguez AP, Rodríguez A, de Bonis E, González-Posada JM, Hernández A, Salido E: Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1726-1733, 1996
29. Bubenicek P, Sotornik I, Vitko S, Teplan V: Early bone mineral density loss after renal transplantation and pre-transplant PTH: a prospective study. Kidney Blood Press Res 31: 196-202, 2008
30. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagos SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439-446, 1999
31. Shimada T, Hasegawa H, Yamazaki Y, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
32. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF-23 levels in ESRD. Clin J Am Soc Nephrol 5: 110-116, 2010
33. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M: Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secobdary hyperparathyroidism. Nephron Clin Pract 101: 94-99, 2005